Johnson & Johnson Presents New Data Reinforcing Sustained Disease Control with IMAAVY in Generalized Myasthenia Gravis

Johnson & JohnsonLatest research data presented at the 2026 European Academy of Neurology Congress further confirm that disease control can be sustained in patients with generalized myasthenia gravis (gMG) treated with IMAAVY.

Key Study-Related Information:

The translated content is provided by third-party software.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making. For accurate information, please refer to the actual announcements. If you have any questions, please contact: biz@staff.sina.com.cn.

Executive Editor: Xiaolang Express